VLX1570

VLX1570 is a competitive inhibitor of proteasome deubiquitinases (DUBs) with an IC50 of approximate 10 μM.

Product Specifications

CAS Number

[1431280-51-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Deubiquitinase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/VLX1570.html

Purity

99.95

Solubility

DMSO : ≥ 32 mg/mL

Smiles

O=C1/C(CN(C(C=C)=O)CC/C1=C\C2=CC=C(F)C([N+]([O-])=O)=C2)=C/C3=CC=C(F)C([N+]([O-])=O)=C3

Molecular Formula

C23H17F2N3O6

Molecular Weight

469.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang X, et al. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des. 2015 Nov;86 (5) :1036-48.|[2]Wang X, et al. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep. 2016 Jun 6;6:26979.|[3]Paulus A, et al. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016 Nov 4;6 (11) :e492.